EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Measuring Objective and Subjective Sleep during Lisdexamfetamine Treatment of Acute Methamphetamine Withdrawal: A Feasibility Study

Liam S Acheson, Christopher Gordon, Rebecca McKetin, Jonathan Brett, Michael Christmass, Craig Rodgers, Nicholas Lintzeris, Adrian Dunlop, Michael Farrell, Steven Shoptaw, Nadine Ezard, Krista J Siefried

European Addiction Research · 2024

DOI: 10.1159/000536328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Addiction Research, 2024. Verfasst von Liam S Acheson und 11 weiteren Autor:innen. Beteiligte Einrichtung: The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Lisdexamfetamine Dimesylate, Substance Withdrawal Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sleep disturbance is common during methamphetamine (MA) use and withdrawal; however, the feasibility of combined subjective-objective measurement of sleep-wake has not been shown in this population. Actigraphy is a well-established, non-invasive measure of sleep-wake cycles with good concordance with polysomnography. This study aimed to investigate the feasibility and utility of using actigraphy and sleep diaries to investigate sleep during MA withdrawal.

Methods

We conducted a feasibility and utility study of actigraphy and sleep diaries during a clinical trial of lisdexamfetamine for MA withdrawal. Participants were inpatients for 7 days, wore an actigraph (Philips Actiwatch 2) and completed a modified Consensus Sleep Diary each morning. Participants were interviewed between days 3–5.

Results

Ten participants (mean age 37 years, 90% male) were enrolled. No participant removed the device prematurely. Participants interviewed (n = 8) reported that the actigraph was not difficult or distracting to wear or completion of daily sleep diary onerous. Actigraphic average daily sleep duration over 7 days was 568 min, sleep onset latency 22.4 min, wake after sleep onset (WASO) 75.2 min, and sleep efficiency 83.6%. Sleep diaries underreported daily sleep compared with actigraphy (sleep duration was 56 min (p = 0.008) and WASO 47 min (p < 0.001) less). Overall sleep quality was 4.4 on a nine-point Likert scale within the diary.

Conclusions

Continuous actigraphy is feasible to measure sleep-wake in people withdrawing from MA, with low participant burden. We found important differences in self-reported and actigraphic sleep, which need to be explored in more detail.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lisdexamfetamine DimesylateSubstance Withdrawal SyndromeHumansMaleAdultFemaleFeasibility StudiesSleepPolysomnographyActigraphy

Stichwörter der Autor:innen

FeasibilityMeasurementMethamphetamineSleepWithdrawal

Substanzen

Lisdexamfetamine Dimesylate

Autor:innen und Institutionen

  • The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Sydney, New South Wales, Australia.
  • Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
  • The National Centre for Clinical Research on Emerging Drugs (NCCRED), c/o the University of New South Wales, Sydney, New South Wales, Australia.
  • Susan Wakil School of Nursing and Midwifery, The University of Sydney, Sydney, New South Wales, Australia.
  • CIRUS Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
  • Clinical Pharmacology and Toxicology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.

Zitieren

APA

Acheson, L. S., Gordon, C., McKetin, R., Brett, J., Christmass, M., Rodgers, C., Lintzeris, N., Dunlop, A., Farrell, M., Shoptaw, S., Ezard, N., & Siefried, K. J. (2024). Measuring Objective and Subjective Sleep during Lisdexamfetamine Treatment of Acute Methamphetamine Withdrawal: A Feasibility Study. European Addiction Research. https://doi.org/10.1159/000536328

Vancouver

Acheson LS, Gordon C, McKetin R, Brett J, Christmass M, Rodgers C, et al. Measuring Objective and Subjective Sleep during Lisdexamfetamine Treatment of Acute Methamphetamine Withdrawal: A Feasibility Study. European Addiction Research. 2024. doi:10.1159/000536328

BibTeX
@article{Acheson2024,
  author = {Acheson, Liam S and Gordon, Christopher and McKetin, Rebecca and Brett, Jonathan and Christmass, Michael and Rodgers, Craig and Lintzeris, Nicholas and Dunlop, Adrian and Farrell, Michael and Shoptaw, Steven and Ezard, Nadine and Siefried, Krista J},
  title = {Measuring Objective and Subjective Sleep during Lisdexamfetamine Treatment of Acute Methamphetamine Withdrawal: A Feasibility Study},
  journal = {European Addiction Research},
  year = {2024},
  doi = {10.1159/000536328}
}
Kostenlos starten →